Evidence map›Paper›PMID 33094375›Full record

ArticleAnnals of surgical oncology2021

The Role of Radiation Therapy in Addition to Lumpectomy and Hormone Therapy in Men 70 Years of Age and Older with Early Breast Cancer: A NCDB Analysis.

Sarah B Bateni, Lauren M Perry, Xiao Zhao, Mili Arora, Megan E Daly, Susan L Stewart, Richard J Bold, Robert J Canter, Candice A M Sauder

Open access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Diseases of the Male Breast: Gynecomastia and Breast Cancer.Deutsches Arzteblatt international · 2025
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sarah B Bateni *Division of Surgical Oncology, Department of Surgery, Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Sacramento, CA, USA.
Lauren M Perry *Division of Surgical Oncology, Department of Surgery, Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Sacramento, CA, USA.
Xiao ZhaoDepartment of Radiation Oncology, Davis Medical Center, University of California, Sacramento, CA, USA.
Mili AroraDivision of Hematology and Oncology, Department of Internal Medicine, Davis Medical Center, University of California, Sacramento, CA, USA.
Megan E DalyDepartment of Radiation Oncology, Davis Medical Center, University of California, Sacramento, CA, USA.
Susan L StewartDepartment of Public Health Sciences, Davis Medical Center, University of California, Sacramento, CA, USA.
Richard J BoldDivision of Surgical Oncology, Department of Surgery, Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Sacramento, CA, USA.
Robert J CanterDivision of Surgical Oncology, Department of Surgery, Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Sacramento, CA, USA.
Candice A M SauderDivision of Surgical Oncology, Department of Surgery, Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Sacramento, CA, USA. camsauder@ucdavis.edu.
University of California Davis Medical Center · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
NCATS NIH HHS UL1 TR001860NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

purposeCurrent treatment guidelines for male breast cancer are guided by female-only trials despite data suggesting distinct clinicopathologic differences between sexes. We sought to evaluate whether radiation therapy (RT) after lumpectomy was associated with equivalent survival among men > 70 years of age with stage I, estrogen receptor (ER) positive tumors, as seen in women from the Cancer and Leukemia Group B (CALGB) 9343 trial.

methodsWe performed a retrospective analysis of 752 stage I, ER-positive male breast cancer patients ≥ 70 years who were treated with hormone therapy and surgery, with or without RT, from the National Cancer Database between 2004 and 2014. Patients were categorized based on surgery and RT (lumpectomy alone, lumpectomy with RT, and mastectomy alone). Multivariable Cox proportional hazards regression analysis was used to compare overall survival between treatment groups.

resultsMost patients underwent total mastectomy, with only 32.6% treated with lumpectomy. Of those who underwent lumpectomy, 72.7% received adjuvant RT. In multivariate analysis, there was no statistical difference in overall survival when comparing lumpectomy alone and lumpectomy with RT (aHR 0.72 [95% CI 0.38-1.37], p = 0.31) or when comparing lumpectomy (alone or with RT) and mastectomy (aHR 1.28 [95% CI 0.88-1.87], p = 0.20).

conclusionsIn this national sample of elderly men with ER-positive early-stage disease treated with endocrine therapy, there were no significant differences in overall survival when comparing lumpectomy alone and lumpectomy with RT, or lumpectomy (alone or with RT) and mastectomy. These results suggest that less aggressive treatment may be appropriate for a subset of male breast cancer patients.

Indexed as

Breast NeoplasmsMastectomy, SegmentalAgedFemaleHormonesHumansMaleMastectomyNeoplasm StagingRadiotherapy, AdjuvantRetrospective StudiesSurvival RateHormones

Identifiers

PMID33094375
PMCPMC8046710
OpenAlexW3094122196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.